NTRK3 and neoplasm: This case report describes a young infant with chemotherapy-refractory, recurrent, ETV6-NTRK3 fusion-positive IFS who experienced rapid, pronounced and durable tumour regression during long-term treatment with larotrectinib, a selective tropomyosin receptor kinase (TRK) inhibitor.